Macro Dynamics - Beijing has issued the first batch of L3-level highway autonomous vehicle special license plates, marking a significant milestone in the country's autonomous driving era. The "conditionally automated driving" feature is currently limited to specific highway sections in Beijing [2] - The State Administration for Market Regulation will soon implement strict regulations on food safety responsibilities for live-streaming e-commerce operators, establishing clear guidelines and penalties for non-compliance [3][4] - By 2026, China plans to build over 10,000 charging guns in highway service areas, with at least 25% being high-power chargers, to enhance electric vehicle charging infrastructure [5] - The Chinese Foreign Ministry has expressed strong opposition to the U.S. adding DJI drones to a restricted list, criticizing the discriminatory practices against Chinese companies [6] - A radioactive water leak occurred at a decommissioned nuclear reactor in Japan, potentially exposing several individuals to radiation [7] Financial Institutions - Hangzhou Bank plans to issue financial bonds not exceeding 40 billion RMB, with a maturity of up to 10 years [8] - The CEO of Bank of America highlighted the increasing impact of AI investments on the U.S. economy, suggesting that AI will play a significant role in future economic contributions [9] Market Data - On December 23, the market experienced a pullback after an initial rise, with the Shanghai Composite Index up by 0.07% and the Shenzhen Component Index up by 0.27%. New stocks listed on the same day saw significant gains [10] - As of December 22, the total margin balance in the two markets increased by 12.534 billion RMB, indicating a growing interest in leveraged trading [11] - The Hong Kong Hang Seng Index closed down by 0.11%, with notable movements in gold stocks and declines in certain tech stocks [12] Company Dynamics - Oriental Yuhong reported that its U.S. subsidiary fell victim to a telecom fraud involving approximately 12.118 million RMB, but the incident is not expected to significantly impact the company's operations [13] - Zhongxin Tourism has established three subsidiaries in Hainan and is actively expanding its tourism-related business in the region [14] - Haohai Biological Technology's controlling shareholder was fined 14.6292 million RMB for insider trading, but this will not affect the company's daily operations [15][16] - The co-founder of the game "Call of Duty," Vince Zampella, tragically passed away in a car accident [17] - Jiangbolong indicated that rising prices of storage wafers would positively impact the company's gross margin, supported by long-term supply agreements with major wafer manufacturers [18]

智通财经APP讯，昊海生科(688366.SH)发布公告，公司控股股东、实际控制人之一蒋伟因内幕交易、 建议他人买卖证券行为，收到中国证监会出具的《行政处罚决定书》，被没收违法所得471万元，并处 以1462.92万元罚款。该处罚决定书所涉主体为蒋伟个人，涉及的事项与公司无关，不会对公司日常经 营、业务及财务造成重大影响。 ...

昊海生科2025年第三季度报告显示，蒋伟系公司第一大股东，直接持股数量为6652.8万股，持股比例为 28.6%；公司第二大股东为游捷，直接持股数量为4032万股，持股比例为17.34%。蒋伟和游捷为夫妻关 系，是公司控股股东、实际控制人。 昊海生科彼时表示，本次事项系对蒋伟个人的调查，其不参与公司日常经营管理，该事项不会对公司日 常经营活动产生重大影响。立案调查期间，蒋伟将积极配合中国证监会开展调查工作。 之后，昊海生科又于2025 年9 月17日公告，蒋伟于近日收到中国证监会出具的《行政处罚事先告知 书》。 昊海生科是一家从事医疗器械和药品研发、生产和销售业务的科技创新型企业，致力于通过技术创新及 转化、国内外资源整合及规模化生产，为市场提供创新医疗产品，逐步实现相关医药产品的进口替代， 成为生物医用材料领域的领军企业。 昊海生科(688366)12月23日晚公告，近日，公司收到控股股东、实际控制人之一蒋伟告知，获悉其收到 了中国证监会出具的《行政处罚决定书》（[2025]151 号）。行政处罚决定书的主要内容为：因蒋伟内 幕交易、建议他人买卖证券行为，中国证监会决定没收其违法所得470.97万 元，并对 ...

北京商报讯（记者 丁宁）12月23日晚间，昊海生科（688366）发布公告称，近日， 公司收到控股股 东、实际控制人之一蒋伟告知，获悉其收到了中国证监会出具的《行政处罚决定书》 。行政处罚决定 书的主要内容为，因蒋伟内幕交易、建议他人买卖证券行为，中国证监会决定没收其违法所得470.97万 元，并对其处以1462.92万元罚款，合计约1933.9万元。 昊海生科表示，该 《行政处罚决定书》 所涉主体为蒋伟个人，涉及的事项与公司无关。蒋伟不参与公 司日常经营管理，该事项不会对公司日常经营、业务及财务造成重大影响。截至公告披露日，公司各项 生产经营活动正常有序开展。 ...

北京商报讯（记者 王寅浩 宋雨盈）12月23日，吴海生科发布公告称，公司控股股东、实际控制人之一 蒋伟因内幕交易、建议他人买卖证券行为，收到中国证券监督管理委员会出具的《行政处罚决定书》， 没收其违法所得470.97万元并处以1462.92万元罚款。根据公告，该《行政处罚决定书》所涉主体为蒋伟 个人，涉及的事项与公司无关。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月23日 第 1 頁 共 11 頁 v 1.3.0 | 1). | 於 2025 年9月15日回購股份但尚未註銷 | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | 10,000 | % | HKD | 27.68 | | | 變動日期 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | 18,400 | % | HKD | 28 | | | 變動日期 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | 23,500 | % | HKD | 27. ...

二、对公司的影响及风险提示 1.该《行政处罚决定书》所涉主体为蒋伟先生个人，涉及的事项与公司无关。 蒋伟先生不参与公司日常经营管理，该事项不会对公司日常经营、业务及财务造 成重大影响。截至本公告披露日，公司各项生产经营活动正常有序开展。 2.有关公司信息以公司指定披露媒体以及上海证券交易所网站刊登的公告 为准。敬请广大投资者注意投资风险。 特此公告。 证券代码：688366 证券简称：昊海生科 公告编号：2025-052 上海昊海生物科技股份有限公司 关于公司控股股东、实际控制人之一因非本公司事项 收到《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）控股股东、实际控制 人之一蒋伟先生此前因非本公司事项，收到中国证券监督管理委员会（以下简称 "中国证监会"）出具的《行政处罚事先告知书》（处罚字[2025]67 号）。具体内 容详见公司 2025 年 9 月 17 日于上海证券交易所网站（www.sse.com.cn）披露的 《上海昊海生物 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 1). | 於 2025 年9月15日回購股份但尚未註銷 | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | 10,000 | % | HKD | 27.68 | | | 變動日期 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | 18,400 | % | HKD | 28 | | | 變動日期 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | 23,500 | % | HKD | 27.63 | | | 變動日期 2025年9月18日 | | | | | | 5). | 於 2025 年9月24日回購股份但尚未註銷 | 51,900 | % | HKD | 27.21 | | | ...

Core Viewpoint - Haohai Biological Technology (688366.SH) plans to acquire approximately 8.466 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (Ruiji Bio), representing 19.8% of Ruiji Bio's total share capital, for about 38.35 million yuan, raising concerns among investors due to the absence of performance commitments or earn-out arrangements [1][4]. Group 1: Acquisition Details - The acquisition is aimed at enhancing Haohai's product portfolio and business resilience, as well as laying the groundwork for the development of innovative material products [3]. - The total valuation of Ruiji Bio in this transaction is approximately 194 million yuan, which reflects a significant premium over its net asset value of several tens of millions [3]. - Haohai will become the sixth largest shareholder of Ruiji Bio after the acquisition, with its major shareholder, You Jie, already holding a significant stake in Ruiji Bio [5][6]. Group 2: Financial Performance of Ruiji Bio - Ruiji Bio has been operating at a loss, with a net profit of approximately -1.18 million yuan in 2024 and -1.13 million yuan in the first three quarters of 2025, indicating a trend of declining financial performance [4][8]. - The company's total assets were about 98.89 million yuan in 2024, with total liabilities of approximately 11.20 million yuan, leading to a net asset value of around 87.69 million yuan [4]. - The revenue for Ruiji Bio was approximately 46.36 million yuan in 2024, with a similar revenue figure of about 46.09 million yuan reported for the first three quarters of 2025, suggesting stagnation in sales [4]. Group 3: Market Context and Strategic Implications - The acquisition allows Haohai to enter the high-value medical device market, specifically in the field of biological amniotic membranes, which are used in orthopedic and ophthalmic applications [7]. - Haohai's recent acquisition of the remaining 20% stake in Shenzhen New Industry Ophthalmology Technology Co., Ltd. indicates a strategic focus on enhancing its presence in the ophthalmic high-value consumables sector [7]. - The company has faced declining revenues across its core business segments, with a reported 7.12% decrease in revenue year-on-year for the first half of the year, driven by factors such as insufficient domestic demand and price competition [8].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...